Clinical trial
Topotecan in Treating Patients With Recurrent, Progressive, or Refractory Cancer…
NCT00025311 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00025311 |
|---|---|
| Title | Topotecan in Treating Patients With Recurrent, Progressive, or Refractory Cancer That is Metastatic to the Lining Around the Brain |
| Official title | A Phase I Study Of Seven Day Continuous Intrathecal/Intraventricular Infusion Of Topotecan For Patients With Recurrent, Progressive Or Refractory Leptomingeal Disease |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | topotecan hydrochloride |
| Start date | May 1, 2001 |
| Primary completion | Oct 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Nov 9, 2012 |
| Countries | France, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: